Sotorasib (AMG510) racemate - 97%, high purity , GTPase KRas inhibitor, CAS No.2252403-56-6, GTPase KRas inhibitor

Item Number
S414293
Grouped product items
SKUSizeAvailabilityPrice Qty
S414293-2mg
2mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$29.90
S414293-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
S414293-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$76.90
S414293-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$155.90
S414293-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$249.90
S414293-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
S414293-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$799.90

Ras Inhibitors

View related series
KRAS Inhibitor

Basic Description

SynonymsSotorasib | AMG-510 | AMG510 | 2296729-00-3 | Lumakras | 2252403-56-6 | AMG-510 racemate | AMG 510 | Kras G12C inhibitor 9 | sotorasibum | 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimid
Specifications & PurityMoligand™, ≥97%
Biochemical and Physiological MechanismsSotorasib (AMG510) racemate is a racemic of AMG-510 which is a potent KRAS G12C covalent inhibitor with potential antineoplastic activity.
Storage TempStore at -20°C,Argon charged
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionGTPase KRas inhibitor
Product Description

Information

Sotorasib (AMG510) racemate Sotorasib (AMG510) racemate is a racemic of AMG-510 which is a potent KRAS G12C covalent inhibitor with potential antineoplastic activity.


Targets

KRAS G12Cv

Product Properties

ALogP4

Associated Targets(Human)

KRAS Tclin GTPase KRas (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NCI-H1975 (4994 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H358 (882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MIA PaCa-2 (5949 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H23 (49055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H1792 (313 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H2122 (340 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KRAS Tclin GTPase KRas (1864 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H1373 (66 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
INCHI InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1
InChi Key NXQKSXLFSAEQCZ-SFHVURJKSA-N
Canonical SMILES CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
Isomeric SMILES C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
PubChem CID 137278711
Molecular Weight 560.59

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

11 results found

Lot NumberCertificate TypeDateItem
L2321302Certificate of AnalysisDec 11, 2023 S414293
L2321304Certificate of AnalysisDec 11, 2023 S414293
L2321305Certificate of AnalysisDec 11, 2023 S414293
L2321307Certificate of AnalysisDec 11, 2023 S414293
L2321309Certificate of AnalysisDec 11, 2023 S414293
L2321374Certificate of AnalysisDec 11, 2023 S414293
L2321375Certificate of AnalysisDec 11, 2023 S414293
L2321378Certificate of AnalysisDec 11, 2023 S414293
L2321383Certificate of AnalysisDec 11, 2023 S414293
L2321384Certificate of AnalysisDec 11, 2023 S414293
L2321385Certificate of AnalysisDec 11, 2023 S414293

more

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro Water: Insoluble; Ethanol: Insoluble; DMSO: 6.25 mg/ml mg/mL

Related Documents

References

1. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS et al..  (2020)  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors..  N Engl J Med,  383  (13): (1207-1217).  [PMID:32955176]
2. Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G et al..  (2020)  Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors..  J Med Chem,  63  (1): (52-65).  [PMID:31820981]

Solution Calculators